Author:
Porreca Ann Marie,Sullivan Kaede V.,Gallagher Jason C.
Publisher
Springer Science and Business Media LLC
Reference93 articles.
1. •• Ben-David D, Kordevani R, Keller N, Tai I, Marzel O, Gal-Mor Y, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2017;18(1):54–60.
https://doi.org/10.1111/j.1469-0691.2011.03478.x.
This article illustrated the impact that carbapenem-resistant K. pneumoniae had on mortality in patients with bloodstream infections.
2. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099–106.
https://doi.org/10.1086/592412
.
3. •• World Health Organization. Global Antimicrobial Resistance Surveillance System. Manual for Early Implementation. WHO. 2015:1–44. http://www.who.int/drugresistance/en/%5Cnwww.who.int/about/licensing/copyright_form/en/index.%5Cnhttp://apps.who.int/iris/bitstream/10665/188783/1/9789241549400_eng.pdf?ua=1. This reference is important because it emphasized the current emergence of Klebsiella pneumoniae carbapenemases globally.
4. • Centers for Disease Control and Prevention. Tracking CRE. CDC. 2017;2010:2009–10.
https://doi.org/10.1086/668770
. This report revealed that all states, with exception of Maine and Idaho, reported cases of Klebsiella pneumoniae carbapenemase-producing organisms
5. • Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59(10):5873–84.
https://doi.org/10.1128/AAC.01019-15
. This paperrevealed how ST258 predominates in the United States and around the world, suggesting a possible selective or fitness advantage over other clones
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献